Phanes Therapeutics Reports the First Patient Dosing with PT886 in P-I/II Study for Pancreatic and Gastric Cancer
Shots:
- Phanes has dosed the first patient with PT886 across the two cohorts, with one focusing on 1L treatment of pancreatic cancer and the other focusing on the 2L treatment of G/GEJ cancer
- The P-I/II (TWINPEAK) trial is assessing the preliminary efficacy, safety, tolerability & PK/PD of PT886 + CT for treating locally advanced or metastatic G/GEJ & pancreatic cancers in patients whose disease progressed post SoC. Another P-I study is underway across China
- PT886 is a FIC IgG-like bispecific Ab that targets CLDN 18.2 & CD47. It was designated with the US FDA’s ODD for pancreatic cancer in 2022 & FTD for metastatic CLDN 18.2+ve pancreatic adenocarcinoma in 2024. Phanes & Merck partnered to assess PT886 + Keytruda for CLDN 18.2+ve G/GEJ cancer
Ref: Phanes Therapeutics | Image: Phanes Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
